Ira Surolia, MD
Medical Oncology · Hartford, CTNPI 1568784718
Payments from drug & device makers
What this record shows
28 manufacturers reported payments, led by AstraZeneca at 47.0% of the total. 2025 is the largest year on record at $1,066, more than ten times the $13 reported in 2020. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.
Across 86 payments — averaging $40.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$217
- Genentech USA, Inc.$172
- Novartis$169
- Janssen Scientific Affairs, LLC$150
- Jazz Pharmaceuticals Inc.$142
- plus $978 from 22 others
What the payments were for
- Consulting fees$1,48543%
- Food & beverage$1,96557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $1,622 |
| AbbVie | 10 | $217 |
| Genentech USA, Inc. | 4 | $172 |
| Novartis | 8 | $169 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 5 | $142 |
| Johnson & Johnson | 8 | $130 |
| Merck | 5 | $92 |
| Daiichi Sankyo Inc. | 5 | $90 |
| Genentech, Inc. | 1 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| EMD Serono, Inc. | 2 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| Eli Lilly | 1 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $45 |
| Bayer | 2 | $43 |
| Mirati Therapeutics, Inc. | 2 | $36 |
| Eisai Inc. | 2 | $30 |
| Tempus AI, Inc | 1 | $30 |
| G1 Therapeutics, Inc. | 2 | $30 |
| Exelixis Inc. | 1 | $24 |
| Emmaus Medical, Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Beigene USA, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,450 in reported general payments places this provider in the 50th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Hartford
- Devendra KcHartford$189
- Michael BurkeHartford$173
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Joseph McLaughlinManchester$200K
- Francine FossNew Haven$193K
- William OhGreenwich$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.